Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance

What is known and objective Some patients with chronic myeloid leukaemia (CML) cannot continue tyrosine kinase inhibitor (TKI) treatment due to intolerance associated with higher plasma concentration. Case summary A 76‐year‐old woman with chronic‐phase CML who showed resistance/intolerance to pre‐TKIs has been treated with ponatinib. A high ponatinib bioavailability was noted; therefore, we administered ponatinib 15 mg/3 d to avoid adverse events due to high exposure. Eventually, the patient achieved a major molecular response. What is new and conclusion Monitoring of the ponatinib plasma concentration led to safe and effective CML management in a patient with higher drug bioavailability.